Zeren T.Ekerbiçer N.2024-07-222024-07-22200410165134http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20053Breast cancer is the most common tumor in women and causes 18% of the cancer related deaths among women in the USA. The five year survival rate of metastatic breast cancer is only 18%. The treatment remains incurable with standard chemotherapy. Epidermal Growth Factor - Receptor (EGF-R) shows tyrosine kinase activity which has been suggested play an significant role on the cell proliferation. Many types of cancer, specially breast cancer, display enhanced EGF-R expression on cell surface membranes. EGF-Receptor may be a suitable target and the inhibitors of protein tyrosine kinases may be useful for therapy of metastatic breast cancer. Genistein (Gen) is a tyrosine kinase inhibitor. Recent studies demonstrated that the conjugation of EGF and Genistein (EGF-Gen) has a cytotoxic activity against breast cancer cells. The specific aim of this study is to examine the anti-tumor efficacy of EGF-Gen conjugate, side by side with standard chemotherapeutic agents (methotrexate, adriamycin, and cyclophosphamide) and the combine activity of EGF-Gen conjugate with standard chemotherapeutic agents in a SCID mouse xenograft model of human breast cancer.Turkishcyclophosphamidedoxorubicinepidermal growth factor receptorgenisteinmethotrexateprotein tyrosine kinase inhibitorarticlebreast cancerbreast metastasiscancer combination chemotherapycancer epidemiologycancer mortalitycancer survivalcytotoxicitydrug efficacyenzyme activityenzyme inhibitionhumannonhumanprotein expressionsurvival rateUnited StatesArticle